In vitro prediction of clinical drug interactions with cyp3a substrates: We are not there yet

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 133-135

  Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HUMANS;

EID: 84893796916     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.230     Document Type: Review

References (11)

1. Rowland, M. & Matin, S.B. Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1, 379-385 (1973).
2. Resetar, A., Minick, D. & Spector, T. Glucuronidation of 3-azido-3-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem. Pharmacol. 42, 559-568 (1991).
3. Tucker, G.T. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 550-553 (1992).
4. von Moltke, L.L., Greenblatt, D.J., Duan, S.X., Harmatz, J.S. & Shader, R.I. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 34, 1222-1227 (1994).
5. Greenblatt, D.J., Venkatakrishnan, K., Harmatz, J.S., Parent, S.J. & von Moltke, L.L. Sources of variability in ketoconazole inhibition of human cytochrome P450-3A in vitro. Xenobiotica 40, 713-720 (2010).
6. Greenblatt, D.J. & von Moltke, L.L. Clinical studies of drug-drug interactions: Design and interpretation. In Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges (eds. Pang, K.S., Rodrigues, A.D. & Peter, R.M.) 625-649 (Springer, New York, 2010).
7. von Moltke, L.L. & Greenblatt, D.J. Clinical drug interactions due to metabolic inhibition: Prediction, assessment, and interpretation. In Enzyme Inhibition in Drug Discovery and Development (eds. Lu, C. & Li, A.P.) 533-547 (John Wiley & Sons, Hoboken, NJ, 2010).
8. Greenblatt, D.J., He, P., von Moltke, L.L. & Court, M.H. The CYP3 family. In Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics (ed. Ioannides, C.) 354-383 (Royal Society of Chemistry, Cambridge, UK, 2008).
9. Obach, R.S., Walsky, R.L., Venkatakrishnan, K., Gaman, E.A., Houston, J.B. & Tremaine, L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316, 336-348 (2006).
10. Vieira, M.d.L.T. et al. Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin. Pharmacol. Ther. 95, 189-198 (2014).
11. Einolf, H.J. et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin. Pharmacol. Ther. 95, 179-188 (2014).